Details

Autor(en) / Beteiligte

• Cassileth, Peter A
• Harrington, David P
• Appelbaum, Frederick R
• Lazarus, Hillard M
• Rowe, Jacob M
• Paietta, Elisabeth
• Willman, Cheryl
• Hurd, David D
• Bennett, John M
• Blume, Karl G
• Head, David R
• Wiernik, Peter H

Titel

Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

Ist Teil von

• The New England journal of medicine, 1998-12, Vol.339 (23), p.1649-1656

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

1998

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The rate of complete remission for adults with acute myeloid leukemia is approximately 65 percent overall and decreases with increasing age and the presence of unfavorable cytogenetic abnormalities. 1 , 2 With postremission therapy, disease-free survival at five years ranges from 10 to 15 percent with low-dose maintenance therapy 2 , 3 to 25 to 35 percent with intensive courses of chemotherapy, usually incorporating high-dose cytarabine. 4 – 6 In young patients, further escalation of postremission therapy is feasible, provided autologous or allogeneic hematopoietic stem cells can be transplanted to repopulate the ablated bone marrow. Despite the complications of graft-versus-host disease, a number of studies suggest . . .